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The expression of hundreds of interferon-stimulated
genes (ISGs) causes the cellular ‘‘antiviral state’’ in
which the replication of many viruses, including
HIV-1, is attenuated. We conducted a screen for
ISGs that inhibit HIV-1 virion production and found
that 20,30-cyclic-nucleotide 30-phosphodiesterase
(CNP), a membrane-associated protein with un-
known function in mammals has this property. CNP
binds to the structural protein Gag and blocks
HIV-1 particle assembly after Gag and viral RNA
have associated with the plasma membrane. Several
primate lentiviruses are CNP-sensitive, and CNP
sensitivity/resistance is determined by a single, natu-
rally dimorphic, codon (E/K40) in the matrix domain
of Gag. Like other antiretroviral proteins, CNP
displays interspecies variation in antiviral activity.
Mice encode an inactive CNP variant and a single
amino acid difference in murine versus human CNP
determines Gag binding and antiviral activity. Some
cell types express high levels of CNP and we specu-
late that CNP evolved to restrict lentivirus replication
therein.
INTRODUCTION
Type I interferon (IFN) stimulates the expression of hundreds of
IFN-stimulated genes (ISGs), causing an ‘‘antiviral state’’ in
which the replication of a broad spectrum of viruses, including
HIV-1, is inhibited (Ho et al., 1985). A handful of well-character-
ized ISGs such as APOBEC3G, TRIM5a, and tetherin are known
to attenuate retroviral replication in vivo (Kirmaier et al., 2010;
Liberatore and Bieniasz, 2011; Okeoma et al., 2007). However,
these factors are evaded in their natural hosts or antagonized
by viral accessory genes (Neil et al., 2008; Sheehy et al., 2002).
Other ISGs, such as ZAP and MOV10, have also been reported
to inhibit retroviral replication in vitro (Furtak et al., 2010; Gao
et al., 2002).Cell HostThe contribution of individual ISGs to the overall antiviral state
remains largely unclear. We have therefore sought to determine
the effect of individual ISGs on HIV-1 replication. Recently, we
reported the results of a screen involving nearly 400 human
ISGs for their capacity to protect permissive cells from HIV-1
infection (Schoggins et al., 2011). During the screening process
we were unable to achieve high levels of transduction with a
subset of ISG-encoding HIV-1-based vectors. We hypothesized
that some of these ISGs might inhibit infectious lentiviral vector
production and, hence, might have specific antiviral activity
against HIV-1.
One such ISG is CNP, which encodes 20,30-cyclic-nucleotide
30-phosphodiesterase. CNP-like proteins are present in diverse
eukaryotes, and although CNP plays a key role in tRNA splicing
in yeast, this is not the case in mammals, where the substrate for
CNP and its role in the life of cells is unknown. CNP is expressed
at low levels in many mammalian tissues, at higher levels in
dendritic cells, and at extremely high levels in oligodendrocytes,
which comprise 40% of the cells in the human brain (Pelvig
et al., 2008; Su et al., 2004; Vogel and Thompson, 1988). Here,
we demonstrate that CNP can specifically inhibit the generation
of infectious particles by several primate lentiviruses, including
HIV-1 and HIV-2. We show that CNP binds to Gag and inhibits
assembly after Gag has associated with the plasma membrane.
The antiviral activity of CNP is highly specific, and naturally
occurring single amino acid variations both in the MA region of
Gag and in the N-terminal region of CNP are key determinants
of CNP antiviral activity. These data suggest that CNP may
have evolved to inhibit the propagation of lentiviruses in partic-
ular cell types.RESULTS
CNP Inhibits theGeneration of InfectiousHIV-1Particles
We have recently described large-scale screens in which indi-
vidual ISGswere delivered to cells using bicistronic HIV-1-based
vectors (Schoggins et al., 2011). During this study, we identified
50 ISG-encoding lentiviral vectors that achieved only poor
transduction. Although many instances of poor transduction
may have been due to cis-acting vector-intrinsic problems, we
noted that some genes with previously described antiviral& Microbe 12, 585–597, October 18, 2012 ª2012 Elsevier Inc. 585
Figure 1. CNP Inhibits HIV-1 in an ISG Screen
(A and B) 293T cells were cotransfected with individual ISG expression vectors (pcDNA DEST40) and the plasmids required to make VSV-G pseudotyped HIV-1
particles. pCMV-HA-GFP was also cotransfected to monitor toxicity. (A) The infectious virion yield was determined by quantifying the number of GFP-positive
MT4 target cells using flow cytometry at 48 hr postinfection. Data are represented asmean ±SEM. (B) Pelletable viral CA (p24) abundance in purified supernatants
as well as Gag precursor (Pr55), CA (p24), and HA-GFP expression in cell lysates were monitored by western blotting.
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CNP Inhibits HIV-1 Virion Assemblyactivity such as APOBEC3G, tetherin, and MOV10 (Furtak et al.,
2010; Neil et al., 2008; Sheehy et al., 2002) were present in this
ISG subset. We therefore hypothesized that other genes from
this subset might specifically interfere with infectious HIV-1
production.
To investigate this possibility, we subcloned these 50
ISGs into a conventional mammalian expression plasmid and
measured their ability to inhibit infectious HIV-1-based lentiviral
vector production when expressed in trans (Figure 1A). Simulta-
neously, HIV-1 Gag protein expression in cells and particulate
capsid (CA) protein in culture supernatant was monitored by
western blotting (Figure 1B). Control antiviral genes, specifically
Rhesus macaque tetherin (MmTHN; Figures 1A and 1B) and
human tetherin mutated to resist Vpu-antagonism (delGI T45I)
(McNatt et al., 2009), reduced infectious particle yield without
affecting Gag expression (Figures 1A and 1B).
Conversely, most of the50 screened ISGs had little effect on
HIV-1 vector production (Figure 1A). Human tetherin, a well-
characterized antiviral restriction factor (Neil et al., 2008) had
only a modest effect because the GagPol expression vector
used also encodes Vpu, which antagonizes its activity. Of the
genes that did reduce infectious virion yield, most decreased
the levels of both Gag and coexpressed HA-green fluorescent
proteins (GFP) (e.g., SLFN12, RARRES3, or OAS3) (Figure 1B).
This was likely a result of global or nonspecific effects, induced
by expressing these genes.
The screen correctly identified APOBEC3G and MOV10 as
antiviral ISGs, both of which reduced infectious virion yield
without inhibiting Gag expression or physical particle produc-
tion, (Furtak et al., 2010; Sheehy et al., 2002). Notably, we also
found that one additional ISG, CNP, also substantially inhibited
infectious particle production (Figure 1A). This effect of CNP586 Cell Host & Microbe 12, 585–597, October 18, 2012 ª2012 Elsevoccurred in the absence of any defect in Gag protein expression
(Figure 1B). However, in contrast to APOBEC3G and MOV10,
and like tetherin, CNP reduced the abundance of particulate
CA protein in the supernatant of transfected cells, suggesting
that CNP functioned at a stage of the virus replication cycle
between Gag expression and virion release.
CNP Inhibits Replication-Competent HIV-1
at Physiological Expression Levels
To determine whether CNP could inhibit replication competent
HIV-1 in the presence of the normal repertoire of accessory
proteins, we coexpressed an HIV-1 proviral plasmid (NL4-3)
with varying amounts of CNP. Infectious particle production
was decreased in a CNP dose-dependent manner, with 100-
fold reduction in infectious virion yield at the highest level of
CNP expression (Figure 2A). In accordance with findings during
the initial screen (Figure 1), CNP expression substantially
reduced particulate CA protein in the supernatant of transfected
cultures by, up to 10- to 50-fold (Figures 2B, S1A, and S1B
available online), but did not affect the total level of cell-associ-
ated Gag protein (Figure 2C). However, Gag processing ap-
peared to be reduced in cells coexpressingCNP, as thepresence
of CNP led to an apparent 2-fold reduction in cell-associated
CA protein and a corresponding increase in the levels of unpro-
cessed Pr55 Gag precursor in cell lysates (Figure 2C). This
apparent reduction in cell-associated Gag processing was likely
a secondary effect of decreased particle assembly, because CA
protein in released virions was processed normally (Figure 2B).
Furthermore, no defect in intrinsic particle infectiousness, or
envelope incorporation into virions, was observed in the pres-
ence of CNP (Figure S1C), again suggesting that CNP affected
thequantity andnot thequality of theparticles thatwere released.ier Inc.
Figure 2. Expression of Catalytically Active
or Inactive, but Not Prenylation-Defective,
CNP at Physiological Levels Reduces Infec-
tious HIV-1 Viron Yield and Gag Processing
(A) 293T cells were cotransfected with an HIV-1
proviral plasmid (pNL4-3) and increasing amounts
of plasmids expressing CNP, catalytically inactive
CNP (NO CAT), and CNP lacking a prenylation
CAAX box (NO PREN). At 48 hr posttransfection,
infectious virion yield was measured using TZM-bl
indicator cells and is plotted as relative light units
(RLU) per ml.
(B and C) Quantitative western blot analysis
(LiCOR) of virion-associated CA (p24) abundance
(B), and cell-associated Gag expression/pro-
cessing (C) was monitored. Charts below the blots
show quantitation of the Pr55 and/or p24 signal in
each lane of the virion (B) and cell lysate (C)
western blots.
(D) Expression of CNP in mouse tissues and
transfected 293T cells was analyzed by western
blotting. Blots were also probed with anti-tubulin
(Tub) as a loading control. See also Figure S1.
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CNP Inhibits HIV-1 Virion AssemblyCNP possesses well-defined catalytic activity (Lee et al.,
2001) and also contains a CAAX box prenylation signal at its C
terminus, which is thought to drive membrane localization. Cata-
lytically inactive mutant CNP (H251A, T253A, H330A, T332A) in-
hibited virion production as effectively as wild-type (WT) CNP
(Figures 2A–2C). In contrast, introduction of a point mutation
(C418A) into the prenylation motif had little effect on CNP ex-
pression levels, but abolished antiviral activity (Figures 2A–2C).
These data suggest that CNP prenylation is essential, but cata-
lytic activity is dispensable, for inhibition of HIV-1 production.
CNP is only weakly induced by type I IFNs (Bartee et al., 2009);
we therefore assessed CNP expression levels in various tissues
to determine whether any expressed sufficient levels to inhibit
particle production in vivo (Figure 2D). Note that the two forms
of CNP visible in Figures 2C and 2D and throughout this study
are generated from alternate translation initiation codons (O’Neill
et al., 1997) (see also Figure 4A). In accordance with the use of
CNP as a marker of differentiated oligodendrocytes (Vogel and
Thompson, 1988), CNP was abundantly expressed in brain
tissue from adult mice (Figure 2D). Notably, expression levels
in adult brain tissue exceeded the maximum level of coex-
pressed CNP used in transfected 293T cells (Figure 2). Thus,
CNP expression levels in oligodendrocytes greatly exceeded
those required to observe antiviral activity. Interestingly, signifi-
cant CNP expression was detected in spleen, thymus, andCell Host & Microbe 12, 585–597,lymph node (Figure 2D), raising the possi-
bility that cells expressing inhibitory levels
of CNPmight also reside in these tissues.
Several, but Not All, Mammals
Encode a CNP that Can Inhibit
a Subset of Lentiviruses
Because retroviral restriction factors
often display species-dependent varia-
tion in antiviral activity that can be ex-
ploited in their characterization, we testedCNP from a panel of mammalian species for their ability to inhibit
a panel of retroviruses. Comparable levels of all CNP variants
were expressed (Figures 3A–3H) and most of those tested
(macaque, African green monkey, cow, and sheep) exhibited
antiretroviral activity. However, murine CNPwas inactive against
any of the viruses tested (Figures 3A–3H).
With the exception of murine CNP, the spectrum of viruses
targeted by CNPwas the same for all the variants tested (Figures
3A–3H). Primate lentiviruses such as SIVMAC239 (Figure 3B),
HIV-2 7312A (Figure 3D) and SIVAGMSAB (Figure 3E) were all
sensitive to CNP to varying degrees. Indeed, SIVMAC239 seemed
particularly sensitive to inhibition by CNP, with infectious particle
production being reduced over 100-fold when coexpressed with
multiple CNP variants (Figure 3B). Furthermore, the apparent
inhibition of HIV-1 Gag processing, evident in the presence of
CNP (Figures 2C and Figures 3A), was more striking in the
case of SIVMAC239 (Figure 3B). Indeed, processed SIVMAC239
CA was barely detectable in the presence of inhibitory variants
of CNP.
The specificity of CNP-mediated inhibition was highlighted
by the resistance of both the nonprimate lentivirus FIV (Fig-
ure 3G) and the gammaretrovirus MLV (Figure 3H). Furthermore,
CNPwas able to distinguish between closely related viruses. For
example, SIVMAC239 and HIV-2 7312A were sensitive to multiple
CNP variants (Figures 3B and 3D) whereas HIV-2 ROD10 wasOctober 18, 2012 ª2012 Elsevier Inc. 587
Figure 3. Spectrum of Antiviral Activity Exhibited by CNP
(A–H) 293T cells were transfected with expression vectors encoding CNP from: Homo sapiens (Human), Macaca mulatta (Macaque), Chlorocebus aethiops
(AGM),Mus musculus (mouse), Bos torus (cow), Ovis aries (sheep), or an empty vector control, in combination with proviral clones (A–D) or plasmids required to
generate single-cycle vectors (E–H). Data are represented asmean ± SEM. At 48 hr after transfection, supernatants were harvested and yields of infectious HIV-1
(A), SIVmac239 (B), HIV-2 ROD10 (C), or HIV-2 7312A were monitored using TZM-bl target cells, as in Figure 2A. Yields of infectious VSV-G pseudotyped GFP-
encoding vectors were determined by titration on MT4 cells for SIVAGMSAB (E), SIVAGMTAN (F), FIV (G), or MLV (H). Gag (A–D) and CNP (A–H) expression in cell
lysates, and particulate CA protein in supernatants (A–D) was monitored by western blotting.
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CNP Inhibits HIV-1 Virion Assemblycompletely resistant (Figure 3C). Similarly, whereas SIVAGMSAB
was inhibited by CNP, SIVAGMTAN was unaffected (Figure 3F).
Importantly, these data indicate that the antiviral activity of
CNP is specific to particular retroviruses, and is therefore unlikely
to be due to generalized perturbation of cell physiology.
A Single Amino Acid Residue that Differs in Murine CNP
Is Required for Antiviral Activity
The observation that murine CNP lacked antiviral activity against
the viruses tested led us to investigate which CNP domains were
critical for its activity. We used SIVMAC239 in these experiments
because it was particularly sensitive to CNP (Figure 3B). Human
CNP is a 422 amino acid protein that shares 85% amino acid
identity with murine CNP (Figure 4A). We first constructed
chimeric CNP molecules by exchanging amino acids 1–224 of
mouse and human CNP (Figure 4B). A chimeric CNP encoding
murine N-terminal and human C-terminal domains (MmHs) had
no antiviral activity, whereas the reciprocal chimera (HsMm)588 Cell Host & Microbe 12, 585–597, October 18, 2012 ª2012 Elsevwas fully active (Figure 4C). Thus, determinants of the antiretro-
viral activity of CNPmapped to the N-terminal half of CNP, which
includes the P loop domain.
Most of the differences between human and murine CNP N
termini were confined to three regions encompassing amino
acids 69–75, 89–99, and 109–118 (Figure 4A). Replacing amino
acids 69–75 (but not amino acids 89–99 or 109–118) in human
CNP with murine counterparts abolished antiretroviral activity,
without affecting expression level (Figures 4 and 4C). Moreover,
when individual amino acid substitutions were made in this
region, a single conservative substitution (D72E, effectively
a three atom [CH2] insertion into the amino acid side chain)
rendered human CNP completely inactive, without affecting
expression levels (Figures 4B and 4C). Although the identity
of residue 72 was critical for CNP activity, it was not the sole
determinant because the corresponding E72D change in
murine CNP failed to confer CNP antiviral activity (data not
shown).ier Inc.
Figure 4. A Single Amino Acid in the N-Terminal P Loop Domain Confers the Antiviral Activity of CNP
(A) Alignment of human and murine CNP proteins, with salient features annotated.
(B and C) 293T cells were cotransfected with a SIVMAC239 proviral plasmid along with plasmids expressing human CNP, mouse CNP, or mutants thereof (B). The
CNPproteins tested included human-mouse chimeras (HsMmandMmHs); humanCNPcontaining regions ofmurine sequence (69–75, 89–99, and 109–118); and
human CNP containing single point mutations (V69L, V71L, D72E, and R75H). (C) At 48 hr posttransfection, infectious virion yield was quantified by titration on
TZM-bl cells. Data are represented as mean ± SEM. Virion-associated CA (p27) as well as CNP and Gag expression/processing in cell lysates was monitored by
western blotting.
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CNP Inhibits HIV-1 Virion AssemblyCNP Targets the MA Domain of the HIV-1 Gag Protein
Following Its Association with the Plasma Membrane
The fact that Gag expression is sufficient to drive VLP formation
led us to consider whether CNPmight directly target Gag. In fact,
CNP inhibited the production of VLPs assembled using either
native codon or codon-optimized (synGag) Gag expression plas-
mids, without affectingGag protein expression levels (Figure 5A).
Because synGag expression is achieved in the absence of HIV-1
genomic RNA sequences, this result suggested that CNP acts
against HIV-1 Gag directly, with no requirement for any other
virally encoded component.Cell HostThe moderate Gag processing defect that was observed
under conditions where CNP reduced particle yield (Figures
2C, Figures 3A, and 3B) is reminiscent of the effects of MAmuta-
tions that reduce membrane binding (Bryant and Ratner, 1990)
suggesting the possibility that CNP might target MA. Indeed,
particle formation driven by an HIV-1 Gag construct, Gag-dGH,
which lacks the majority of MA (amino acids 7–110) (Perez-
Caballero et al., 2004), was resistant to inhibition by CNP (Fig-
ure 5B). Based on these results, we next examined whether
transferring the MA region of HIV-1 to MLV, a virus that is ordi-
narilyCNP-resistant, (Figure 3H),might confer sensitivity. Indeed,& Microbe 12, 585–597, October 18, 2012 ª2012 Elsevier Inc. 589
Figure 5. CNP Targets the MA Domain of HIV-1 Gag and Block Assembly after Gag Reaches the Plasma Membrane
(A) Effect of CNP on VLP production driven by native codon (Gag) or codon optimized (synGag) expression, as determined by western blot analyses of 293T cell
cultures transfected with Gag and CNP expression plasmids.
(B) Effect of CNP on VLP production driven by HIV-1 Gag or Gag dGH expression, as determined by western blot analyses of 293T cell cultures transfected with
Gag and CNP expression plasmids.
(C) Effect of CNP on VLP production driven by plasmids required to make VSV-G pseudotyped single cycle MLV vectors, using either an MLV GagPol expression
plasmid or MLV GagPol in which MA was substituted with HIV-1 MA. Infectious virion yield was quantified by titration on MT4 cells Data are represented as
mean ± SEM. Particulate MLV CA in culture supernatants as well as CNP and Gag expression/processing in cell lysates were assessed by western blotting.
(D) Western blot analysis of CNP and HIV-1 Gag abundance after fractionation (lanes 1–10) of 293T cell lysates on a membrane flotation gradient following
cotransfection with plasmids expressing HIV-1 Gag, a packageable HIV-1 vector genomic RNA and CNP or nonprenylated CNP (NO PREN). PNS, unfractionated
postnuclear supernatant.
(E) Viral genomic RNA abundance determined by RT-qPCR analysis of the same fractions as in (D) is shown.
(F) Representative images of 293T cells 24 hr after cotransfection with plasmids expressing either CNP or CNP lacking a prenylation sequence (NO PREN), along
with plasmids encoding Gag and Gag-GFP (in a 5:1 ratio).
(G) Quantification of fluorescent puncta in three fields from ten randomly selectedGag/Gag-GFP andCNP expressing cells. The number of puncta per 100 mm2 for
each individual cell is plotted. Horizontal lines represent mean values.
(H) Western blot analysis of Gag, CNP, and a-tubulin expression in cells, and VLP abundance in culture supernatants for cells treated identically to those
examined in (F) and (G).
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CNP Inhibits HIV-1 Virion Assemblythis manipulation conferred CNP-sensitivity, and CNP reduced
the yield of infectious virions assembled using the chimeric Gag
by 50-fold (Figure 5C). Thus, the MA region of Gag is the key
determinant of sensitivity to CNP.
The efficiency of Gag multimerization, and thus assembly, is
greatly enhanced by Gag association with both the plasma
membrane (Kutluay and Bieniasz, 2010) and with viral or cellular
RNAs. Because (1) MA directs Gag to membranes and was a
key determinant of CNP sensitivity (Figures 5B and 5C), (2)
CNP is a membrane-anchored RNA binding protein, and (3) the
CNP membrane anchor (prenylation) was essential for antiviral
activity (Figure 2), we investigated whether CNP affected the
ability of HIV-1 Gag to associate with membranes, or inhibited
the ability of Gag to recruit HIV-1 genomic RNA. Interestingly,
under conditions where particle assembly was blocked by
CNP, there was little effect on the subcellular distribution of
Gag, as assessed by fractionation of Gag-expressing cells on
a membrane flotation gradient (Figure 5D). Specifically, Gag
was readily detectable in the membrane fraction (fraction 3) of
cells coexpressing either WT CNP or inactive nonprenylated
CNP (Figure 5D). In contrast, the abundanceof the nonprenylated
mutant of CNP in membrane fractions was greatly diminished
(Figure 5D). These data indicate that even though MA is a key
sensitivity determinant, CNP does not inhibit the ability of Gag
to associate with membranes. Nonetheless, CNP-membrane
association seemed to be required for antiviral activity.
We previously described an assay in which RT-qPCR is
coupled with membrane flotation analysis to measure the distri-
bution of HIV-1 RNA in infected cells (Kutluay and Bieniasz,
2010). Using this assay, we found that CNP did not affect the
ability of Gag to recruit genomic RNA to membranes (Figure 5E).
Overall, these findings indicated that CNP inhibits particle
production subsequent to a key early event in virion assembly,
namely the association of Gag and viral genomic RNA with the
plasma membrane.
To further delineate the step at which CNP acts, we used
a microscopy-based approach. Assembly of morphologically
accurate, individual HIV-1 VLPs can be readily visualized by
fluorescence microscopy using coexpressed Gag and Gag-
GFP fusion proteins (Jouvenet et al., 2008; Larson et al., 2005).
Normally, Gag-GFP that is initially diffuse concentrates at
sites of virion assembly, forming bright fluorescent puncta.
In the presence of nonprenylated, inactive CNP, distinctive
puncta of Gag-GFP could be readily observed (Figure 5F) and
quantified (Figure 5G). Moreover, extracellular VLP production
proceeded efficiently (Figure 5H). However, in the presence of
CNP, a striking paucity of puncta was observed on the cell
surface (Figure 5F). Quantitative analysis revealed that the
abundance of VLPs had been reduced 20-fold by CNP coex-
pression (Figure 5G). A simultaneous, dramatic reduction in
extracellular VLP yield was also observed, whereas the overall
level of Gag/Gag-GFP expression was unaffected by CNP (Fig-
ure 5H). Once again, Gag-GFP accumulation at the plasma
membrane appeared abundant even in the presence of CNP,
however, the Gag-GFP was diffusely distributed at the plasma
membrane and failed to coalesce into puncta (Figure 5F). These
data reinforce the conclusion that CNP inhibits HIV-1 virion
assembly subsequent to the association of Gag with the plasma
membrane.Cell HostSelection of a CNP-Resistant HIV-1 Mutant
The rapidity of HIV-1 evolution often makes it possible to isolate
mutants in vitro that are resistant to inhibitors. We askedwhether
HIV-1 could evolve resistance to CNP following cultivation in the
presence of CNP. Derivatives of MT4 T cells expressing similar
levels of either active CNP or inactive (nonprenylated) CNP
were generated (Figure 6A) and then infected with a replica-
tion-competent HIV-1 clone in which Nef was replaced with
EGFP (NHG, GenBank accession number: JQ585717). MT4 cells
are unusually permissive to HIV-1 replication, and unmodified
cells, or cells expressing nonprenylated CNP, became nearly
100% infected between day 3 and day 4 after inoculation (Fig-
ure 6B). However, HIV-1 replication was delayed in MT4 cells
expressing the intact CNP protein, with the majority of cells re-
maining uninfected on day 5 (Figure 6B). This result highlights
the ability of CNP to inhibit the spread of HIV-1.
HIV-1 propagated in the presence of CNP was harvested on
day 6, and following three subsequent passages in MT4 cells
expressing CNP, an isolate was obtained that replicated with
indistinguishable kinetics in the presence or absence of CNP
(Figure 6C). Interestingly, this CNP-adapted isolate also repli-
cated with near-identical kinetics to the parental HIV-1 clone in
unmodified MT4 cells (Figures 6B and 6C). Sequencing of
PCR-amplified proviral gag DNA identified a single G to A transi-
tion that had apparently been selected to near uniformity in the
CNP-resistant isolate. This single nonsynonymous change
altered codon 40 in the MA region of Gag from glutamate (50-
GAG-30) to lysine (50-AAG-30) (Figure 6D). This change is hence-
forth referred to as E40K. When this single amino acid change
was introduced into the parental HIV-1 clone, replication in
primary lymphocytes was impaired only marginally in one donor,
and not at all in a second (Figure 6E). Moreover, the E40K muta-
tion did not substantially alter envelope incorporation into virions
(Figures S2A–S2C). This suggested that resistance to CNP was
acquired without incurring a major replicative fitness cost.
Importantly, the E40K mutation was sufficient to confer
complete resistance to the inhibitory effects of CNP on infectious
virion production from both 293T cells (Figure 6F) and MT4 cells
(Figures S2D and S2E). E40 is exposed on the surface of the
globular head of myristoylated MA (Tang et al., 2004), and is
positioned close to, but not precisely coincident with the posi-
tively charged surface that is thought to participate in membrane
binding (Figure 6G). Moreover, E40 is positioned toward the inte-
rior of the trimer structure that is adopted by MA in crystals (Hill
et al., 1996). A survey of the variation at E40 in an alignment of
primate lentiviruses (http://www.hiv.lanl.gov) revealed that this
position is dimorphic in primate lentiviruses and the amino acid
identity at this position (Figure 6D) correlated precisely with
primate lentivirus sensitivity to CNP (Figure 3). Whenever E40
was present, the virus was sensitive to CNP (HIV-1, SIVMAC239,
SIVAGMSAB, and HIV-2 7312A), and whenever K40 was present,
the virus was resistant (HIV-2 ROD10 and SIVAGMTAN) (Figures 3
and Figures 6D). Taken together, these data strongly suggest
that HIV-2 ROD10 and SIVAGMTAN are resistant to CNP because
they encode a lysine residue at the equivalent position to HIV-1
E40K. Notably, the vast majority of primate lentiviruses encode
glutamate at position 40 and are therefore predicted to be
CNP sensitive. Only rare examples of HIV-2, SIVAGM, and SIVRCM
encode K40 and are therefore predicted to be CNP-resistant.& Microbe 12, 585–597, October 18, 2012 ª2012 Elsevier Inc. 591
Figure 6. Selection and Characterization of
a CNP-Resistant HIV-1 Gag Mutant
(A) Western blot analysis of CNP expression in
MT4 cells stably expressing intact CNP, or
CNP lacking a prenylation sequence (NO PREN),
generated by retroviral transduction.
(B and C) Replication of GFP-encoding HIV-1
(NHG) (B), or NHG passaged on CNP expressing
cells (C), on CNP-expressing MT4 cells is shown,
as the percentage of infected cells determined by
flow cytometry.
(D) An alignment primate lentiviral MA sequences
encompassing the E40K (highlighted) substitution,
numbered according to HIV-1 (NL4-3).
(E) Replication of WT (filled symbols) and E40K
mutant (open symbols) HIV-1 (NHG) in peripheral
blood mononuclear cells from two donors, moni-
tored by assaying reverse transcriptase activity in
culture supernatants.
(F) Infectious virion yield, quantified by titration on
MT4 cells following cotransfection of 293T cells
with plasmids expressing CNP along with WT or
E40K mutant NHG. Data are represented as
mean ± SEM. Virion-associated CA (p24) aswell as
CNP and Gag expression/processing in cell
lysates was monitored by western blotting.
(G) A structural representation (Protein Data
Bank [PDB] ID: 1UPH) of the monomer myr-
istoylated MA region of Gag (Tang et al., 2004).
Basic residues from the MA basic region are
highlighted in blue and the dimorphic position
40 is highlighted in red. Also shown is the
trimeric crystalline form of MA (PDB ID: 1HIW)
with position 40 highlighted in red (Hill et al.,
1996).
(H) Purified HIV-1 virions from the experiment
shown in (F) were normalized for p24 content, and
subjected to western blot analysis using anti-
bodies to p24 and CNP. See also Figure S2 and
Table S1.
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CNP Inhibits HIV-1 Virion AssemblyCNP is expressed at low, subinhibitory levels in many cell
types. For example, CNP is barely detectable in 293T cells (Fig-
ure 2). Nevertheless, CNP is among the more abundant proteins
detected by mass spectroscopic analysis of purified HIV-1
virions derived from 293T cells (Table S1) and is also found in
macrophage-derived virions (Chertova et al., 2006). Therefore,
we examined the degree to which CNP was incorporated into
HIV-1 particles when expressed at inhibitory levels, using the
active (human) and inactive (murine) CNP proteins as well as
sensitive (E40) and resistant (K40) HIV-1 strains. Because over-
expressed CNP inhibits the assembly of WT HIV-1, there were
fewer particles generated by cells coexpressing human CNP
(Figure 6F). However, when equal numbers of virions were
analyzed (based on particulate CA quantities, Figure 6H), human
CNP was easily detected in WT virions, whereas the inactive
murine CNP was largely absent (Figure 6H). In addition, CNP
was also largely absent from E40K mutant virions. Importantly,
virion-associated CNP was resistant to digestion by subtilisin
indicating that it is packaged into the interior of virions (Fig-
ure S2F). Together, these data suggest that CNP associates592 Cell Host & Microbe 12, 585–597, October 18, 2012 ª2012 Elsevwith virions, specifically when active CNP and a CNP-sensitive
Gag protein are present and is efficiently incorporated into
virions if assembly is completed.
CNP Binds Directly to HIV-1 Gag and Blocks an Early
Step in Virion Assembly
To further examine whether CNP associates with assembling
virions, we used fluorescent microscopy to determine whether
CNP and Gag-mCherry fusion proteins colocalize in transfected
cells. Because antiviral doses of CNP inhibit the formation of Gag
puncta (Figures 5F and 5G) that would complicate analyses of
colocalization, we used a low, subinhibitory dose of coex-
pressed CNP. A high degree of colocalization between CNP
and Gag-mCherry was observed, with a mean Pearson’s coloc-
alization coefficient of 0.6 (Figures 7A and 7C). Notably, CNP
exhibited a greatly reduced degree of colocalization with the
CNP-resistant E40K Gag mutant, with a mean colocalization
coefficient value of 0.2 (Figures 7B and 7C). The data suggest
that WT, but not CNP-resistant, Gag recruits CNP to sites of
particle assembly.ier Inc.
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CNP Inhibits HIV-1 Virion AssemblyCumulatively, our findings suggested that CNP might inhibit
particle assembly by binding directly to Gag. Importantly, the
identification of an inactive point mutant CNP (D72E) and
a CNP-resistant Gag point mutant (E40K) provided specificity
controls to investigate this question. Our initial attempts to
specifically coprecipitate CNP with a Gag-glutathione-S-trans-
ferase (GST) fusion protein, coexpressed in 293T cells, proved
unsuccessful. However, when cellswere treatedwith a crosslink-
ing reagent (ethylene glycol bis[sulfosuccinimidylsuccinate],
EGS) prior to glutathione-Sepharose precipitation, crosslinked
CNP:Gag-GST complexes were readily detected in the precipi-
tates (Figure 7D). The crosslinked proteins included one species
of a size (130 kDa) that suggested the formation of a complex
containing only one CNP molecule (48 kDa) and one Gag-GST
(82 kDa) molecule, as well as higher molecular weight forms that
may have contained multiple copies of Gag-GST and/or CNP or
other proteins (Figure 7D). The apparent formation of a130 kDa
1:1 CNP:Gag-GST complex, using an EGS crosslinker that is
only 16 A˚ in length, strongly suggested that CNP and Gag-
GST bound directly to each other. Importantly, the formation of
the CNP:Gag-GST complexes was remarkably specific. Only
trace amounts of CNP(D72E):Gag-GST or CNP:Gag(E40K)-
GST complexes were formed (Figure 7D). Thus, the specificity
with which CNP:Gag-GST complexes formed precisely recapit-
ulated the specificity that the antiviral effects of CNP were
observed.
The findings that CNP bound to Gag (Figure 7D), and impeded
the coalescence of Gag-GFP fluorescent puncta (Figures 5F and
5G) led us to consider whether CNPmight induce the accumula-
tion of incomplete budding structures or misformed assembly
intermediates that were not detectable by fluorescence micros-
copy. To examine this possibility, we utilizedMT4 cells stably ex-
pressing CNP (Figures 6A–6C and Figures 7E). In this context,
the CNP expression level is comparable to intermediate levels
used in cotransfection experiments (Figure 7E) and causes
submaximal inhibition of particle assembly. We reasoned that
this condition would increase the likelihood of observing
abnormal virions or assembly intermediates. CNP-expressing
cells were infected with equivalent titers of CNP-sensitive (WT)
or CNP-resistant (E40K) HIV-1 (both encoding GFP in place of
nef) yielding 65% infected cells (Figure S3A) and examined
using thin section electron microscopy (Figures 7F–7H). The
fraction of cells on which virions were observed was reduced
2-fold inWTHIV-1 infected cells as compared to CNP-resistant
(E40K) HIV-1 infected cells (Figure 7G). Moreover, when the
number of virions associated with producing cells was counted,
this number was 5-fold reduced for WT HIV-1 infected cells as
compared to CNP-resistant (E40K) HIV-1 infected cells (Fig-
ure 7H). Thus, the overall observed reduction in the number of
virions observed in WT HIV-1 infected cells as compared to
CNP-resistant (E40K) HIV-1 infected cells was 10-fold, entirely
consistent with the reduction in WT HIV-1 particle production
observed in the same cells using western blot assays (Figure 7I).
Importantly, the morphology of virions and budding structures
were indistinguishable regardless of whether CNP-sensitive or
-resistant viruses were considered. In particular, although WT
virions were fewer in number than CNP-resistant virions, they
were generally of the correct size and morphology (Figure S3B).
These data suggest that when CNP successfully inhibits HIV-1Cell Hostassembly it does so at an early stage, i.e., before electron dense
structures (Figures 7F–7H) or fluorescent punta (Figures 5F and
5G) become detectable. ‘‘Breakthrough’’ particles that do
assemble in the presence of CNP apparently achieve normal
morphology and infectiousness.
DISCUSSION
Here we report a function for the phosphodiesterase enzyme
CNP, namely the ability to bind to Gag and potently block the
assembly of HIV-1 and several other primate lentiviruses. CNP
apparently inhibits assembly by binding to Gag in a highly
specific manner, as single amino acid substitutions in either
MA or CNP abolished both binding and antiviral activity. Notably,
single amino acid substitutions in MA have previously been
proposed to govern host-specific adaptation of HIV-1/SIVcpz
to human versus chimpanzee hosts (Wain et al., 2007), but at a
different position to E40K. Moreover, because human and chim-
panzee CNP protein sequences are identical, CNP is unlikely to
underlie that particular host adaptation.
Even though CNP apparently targets MA, it inhibited virion
assembly at a step subsequent to Gag association with the
plasma membrane. At this stage of the virus lifecycle, Gag mole-
cules and the viral genome are poised to coalesce into nascent
particles. Our findings suggest that high levels of CNP impede
the normal higher-order multimerization of Gag molecules that
accompanies particle formation. We speculate that inhibition
is the result of a steric effect, whereby CNP-Gag interactions
inhibit Gag multimerization. Because the CNP-resistant E40K
MAmutant has lost the ability to bind CNP, and no longer coloc-
alizes with CNP at the plasma membrane, it is likely that Gag-
CNP binding recruits CNP to budding sites, and that the E40K
mutation results in the loss of a CNP binding site on Gag.
However, we cannot formally exclude the alternative possibility
that E40K Gag preferentially assembles at membrane microdo-
mains that have a paucity of CNP, and that this underlies the
absence of interaction between CNP and E40K Gag.
Although CNP-like proteins are present in diverse eukaryotes
(from yeast to man), they have clearly evolved to take on different
biological functions. In yeast, a CNP ortholog is required in tRNA
splicing, and CNP is expressed as part of a multifunctional
enzyme that includes tRNA ligase, 50-OH kinase, and CNP-like
domains. In mammals, as in yeast, CNP is an enzyme that can
catalyze the hydrolysis of 20,30-cyclic nucleotides to produce
20-nucleotides (Sakamoto et al., 2005). However, CNP is not
required for tRNA splicing in mammals, and lacks the RNA ligase
domain. Indeed, the physiologically relevant substrate and the
biological role of CNP in mammalian cells are unknown. The
catalytic activity of CNP is dispensable for antiviral activity, but
the absolute conservation of the H-X-T-X catalytic residues
suggests that CNP has functions in addition to antiretroviral
activity. In fact, mice lacking CNP expression suffer from neuro-
degeneration in later life and premature death (Lappe-Siefke
et al., 2003), but the underlying causes of this phenotype are
not known.
Although inhibitory expression levels of CNP in transfected
cells are well within the levels observed in certain murine tissues
in vivo (Figure 2), no cultured human cell lines express these high
levels of CNP. Therefore, we were not able to address the role of& Microbe 12, 585–597, October 18, 2012 ª2012 Elsevier Inc. 593
Figure 7. CNP Binds Gag and Inhibits HIV-1 Particle Production
(A and B) Representative images (acquired at the cell-coverslip interface) of 293T cells coexpressing CNP along with WT (A) or E40K (B) Gag and Gag-mCherry,
and stained using Alex Fluor 488 labeled anti-CNP.
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CNP Inhibits HIV-1 Virion Assemblyendogenously expressed CNP in limiting HIV-1 replication.
Based on microarray analyses of human tissues, the only cells
outside the brain that express significant levels of CNP are
dendritic cells (Su et al., 2004). Thus it seems unlikely that CNP
exerts strong inhibition of HIV-1 replication in vivo. It seems
more likely that CNP is an ‘‘orphan’’ restriction factor whose anti-
viral potential is underexploited by the hosts of lentiviruses. If this
is the case, then CNP exemplifies the huge antiviral potential of
the mammalian genome, and it is possible that CNP constitutes
part of the ‘‘raw material’’ from which restriction factors evolve.
On the other hand, very little is known about the tropism of
ancestral primate lentiviruses, and the discovery of an ancient
endogenous SIV (that, by definition, infected germ-line cells)
(Gifford et al., 2008) implies that acquisition of strict tropism of
primate lentiviruses for CD4+ cells is a relatively recent occur-
rence. Thus, we speculate that CNP may have targeted ancient
neurotropic lentiviruses, perhaps to protect the brain from
damaging infection. Consistent with this idea, the simpler lenti-
virus, Maedi Visna virus, is oligodendrocyte-tropic (Stowring
et al., 1985). In addition, beyond HIV-1, HIV-2, and SIVMAC, little
is known about neurotropism of primate lentiviruses in their
normal hosts. It remains possible that some contemporary
primate lentiviruses might exploit the oligodendrocyte niche
and replicate in cells that express high levels of CNP.
The great interest in identifying and characterizing retroviral
restriction factors in recent years has identified the recurrent
theme that restriction factors must either be antagonized or
avoided in their natural host. Evasion of a restriction factor could
occur at the molecular level, for example by varying a protein
surface to avoid restriction factors. Alternatively, viral tropism
could be selected so as to avoid the restriction factor altogether.
In the case of CNP, both evasion or avoidance strategies appear
possible. At the molecular level, the occasional appearance of
K40 (e.g., in SIVAGMTAN) may be a means of evading CNP.
Likewise, the tropism of primate lentiviruses might have evolved
to avoid replication in cells expressing high levels of CNP.
In conclusion, CNP is a host protein that is clearly capable of
inhibiting the assembly of HIV-1 and other primate lentiviruses.
Although the identity of viruses that have been, are, or will be
targeted by CNP remain elusive, this study illustrates an entirely
unanticipated mechanism by which host factors can interfere
with virus replication. Whether the antiviral potential provided
by host gene products can be exploited or mimicked in the
context of gene-based or pharmaceutical therapy remains to
be determined.(C) Quantitative analysis of colocalization. Each symbol in the graph is the Pearso
value. Expanded images from the cell-coverslip interface are also shown.
(D) Western blot analysis (aCNP or aGST) of glutathione-Sepharose precipitates a
WT or mutant CNP, GST, or Gag-GST proteins. Molecular weight markers indica
(E) Quantitative western blot analysis of 293T cells transiently transfected with the
stably expressing CNP. Numbers above each lane indicate the relative band inte
(F) Electron microscopic images of CNP expressing MT4 cells infected with HI
representative images for each are shown).
(G) Percentage of infected cells that exhibited associated virions. One square of
(H) Quantification of the number of virions and budding structures on infectedMT4
associated virions were evaluated.
(I) Quantitative western blot analysis of virion yield, CNP, and Gag expression in M
above each lane indicate the relative band intensities (LiCOR). See also Figure S
Cell HostEXPERIMENTAL PROCEDURES
Additional details of the experimental procedures are given in the Supple-
mental Experimental Procedures.
Plasmid Construction
The library of ISGs (Figure 1) were inserted into a CMV promoter-driven
expression vector (pcDNA DEST40, Invitrogen) using the Gateway procedure,
according to manufacturers instructions. CNP cDNAs from the various
mammalian species were amplified by PCR and cloned using oligonucleotide
derived SfiI sites into Gateway-compatible entry vectors prior to transfer to a
CMV promoter-driven expression vector (pcDNA-DEST40, Invitrogen) for
transfection. Mutant CNP expression plasmids, and a mutant HIV-1 proviral
plasmid (NHG, that carries GFP in place of nef) bearing the E40KMAmutation,
were generated using PCR-based mutagenesis and oligonucleotides detailed
in the Supplemental Experimental Procedures.
Cell Lines and Transfection
Cell lines and peripheral blood mononuclear cells were maintained under
standard conditions. MT-4 cell clones expressing CNP were generated by
transduction with retroviral vectors, puromycin selection, and single cell
cloning by limiting dilution. Clones were subsequently maintained in medium
supplemented with puromycin. All transfection experiments were performed
in 293T cells, which were seeded in 24-well plates at a concentration of
2.5 3 105 cells/well and transfected the following day using polyethylenimine
(PolySciences).
Virus Release and Infectivity Assays
For the ISG screen (Figure 1), 293T cells were cotransfectedwith individual ISG
expression vectors and plasmids required to make VSV-G-pseudotyped,
GFP-expressing HIV-1 vector particles. In addition, a plasmid-expressing
HA-GFP was also cotransfected.
To measure the effect of CNP on virus particle production, cells were
transfected with increasing or fixed amounts of a CNP expression plasmid
along with plasmids required to generate infectious retrovirus particles or
VLPs.
In all transfection experiments, the total amount of DNA was held constant
within the experiment by supplementing the transfection with an empty
expression vector. At 48 hr posttransfection, virion-containing culture super-
natants were harvested, clarified by low speed centrifugation, and filtered
(0.22 mm). Particle release was evaluated using western blot analysis of cell
lysates and pelleted virions using an anti HIV-1 p24 CA antibody. Infectious
virions were quantified by inoculating TZM-bl indicator cells followed by
b-galactosidase assay or, in cases where the viral genome encoded GFP,
by inoculating MT4 cells and enumerating infected cells by FACS.
HIV-1 Adaptation and Replication Assays
MT4 cells were infected with HIV-1 (NHG) and infection monitored by FACS
analysis. Culture supernatants were used to inoculate fresh MT4 cells when
the majority of the cells became infected. Replication of WT or E40K mutant
HIV-1 in human peripheral blood mononuclear cells was monitored using
reverse transcriptase assays.n’s coefficient for an individual cell and the horizontal line represents the mean
nd cell lysates from crosslinker-treated 293T cells, coexpressing the indicated
te the mass in kDa.
indicated amount of a CNP expression vector (from Figure 2B) and MT4 cells
nsities (LiCOR).
V-1, or the CNP-resistant HIV-1 point mutant E40K, 48 hr postinfection (two
a 200 mesh grid (20 cells) was counted for each data point.
cells. Each data point represents an individual cell, and only cells that exhibited
T4 CNP cells identically infected in parallel with those used in (F–H). Numbers
3.
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Glutathione-Sepharose precipitates, virion and cell lysates, or tissue extracts
were separated on 4%–12% acrylamide gels, blotted onto nitrocellulose
membranes, and probed with anti-HIV-1-p24CA (183-H12-5C), anti-CNP
(Millipore), or anti-tubulin primary antibodies (Sigma).
Subsequently, blots were probed with peroxidase-labeled goat anti-mouse
antibodies or with fluorescent goat anti-mouse IRdye 800CW antibodies
(Li-COR) prior to visualization by exposure to film or quantitation using an
Odyssey infrared imaging system (Li-COR).
CNP Expression in Tissues
Tissues from 16-day-old and 1-day-old C57BL/6 mice were harvested, and
digested where necessary with proteinase K prior to isolating single-cell
suspensions using a cell strainer. The tissue samples were then lysed in
RIPA buffer (150 mM NaCl, 50 mM Tris [pH 7.4], 0.1% SDS, 1 mM EDTA,
1% Igepal CA-630, 1% Na deoxycholate, and protease inhibitors), diluted in
protein sample buffer, and sonicated. CNP expression was assessed by
western blotting as described above.
Membrane Flotation Assay
Cells expressing HIV-1 Gag, a packageable viral genome and CNP were
generated by transfection of HEK293T cells with a vector genome expressing
plasmid (V1B) (Kutluay and Bieniasz, 2010) along with plasmids expressing
Gag and CNP. They were then subjected to membrane flotation assay as
previously described (Kutluay and Bieniasz, 2010; Spearman et al., 1997) (as
detailed in the Supplemental Experimental Procedures). Gradient fractions
were probed for the presence of Gag and CNP proteins using western blot
assays, as well as viral RNA, using quantitative RT PCR assays as described
previously (Kutluay and Bieniasz, 2010).
Fluorescent and Electron Microscopy
Cells, seeded in glass-bottomed dishes were transfected with HIV-1 Gag,
Gag-GFP, Gag-mCherry, and CNP expression vectors. They were then immu-
nostained where necessary, using an anti-CNP antibody and observed by
deconvolution microscopy, as described previously (Jouvenet et al., 2006).
Puncta of Gag-GFP from randomly selected fields were counted and
Pearson’s colocalization coefficients derived, as described in the Supple-
mental Experimental Procedures. Thin section EM of HIV-1-infected MT4 cells
was carried out using previously described methods (Zhang et al., 2009), as
detailed in the Supplemental Experimental Procedures. The number of virions
per cell was determined by counting the number of virus like structures (virions
and budding structures) per cell, using randomly selected cells that were
adjudged to have at least one definitive virus-like structure. The percentage
of virion producing cells per square of a 200 Mesh EM grid was calculated
by counting the number of cells with or without definitive associated virion
structures. Approximately 20 cells each from five different squares (a total of
100 cells) were sampled for each condition.
Crosslinking and Precipitation Analyses
293T cells expressing CNP and Gag-GST were treated with ethylene glycol
bis[succinimidylsuccinate] (EGS) crosslinker, and glutathione-Sepharose
precipitates prepared as previously described (Eastman et al., 2005; Kutluay
and Bieniasz, 2010). The precipitates were analyzed by western blotting, as
described above.
Analysis of Protein Incorporation into Virions
To assess the incorporation of Env protein or CNP into virions, virions were
harvested from transfected 293T cells and subjected to western blot analysis,
as described above, and detailed in the Supplemental Experimental Proce-
dures. To assess whether CNP was incorporated into the interior of particles,
purified virions were treated with subtilisin prior to western blot analysis, as
detailed in the Supplemental Experimental Procedures.
For mass spectrometry analysis of virions, particles were harvested from the
supernatant of infected 293T cells by ultracentrifugation onto a sucrose
cushion, then separated on an Optiprep gradient. Proteins in each of ten
gradient fractions were precipitated with trichloroacetic acid and separated
by gel electrophoresis. A fraction containing the majority of the virions was
identified, and gel pieces comprising the entire lane were analyzed using596 Cell Host & Microbe 12, 585–597, October 18, 2012 ª2012 Elseva using an Orbitrap XL mass spectrometer, as described in the Supplemental
Experimental Procedures.ACCESSION NUMBERS
The Genbank accession numbers for Ovis aries CNP and Chlorocebus
aethiops vervet CNP reported in this paper are JN684760 and JN684759,
respectively. The Genbank accession of the HIV-1 NL43/HXB2 recombinant
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